LM Advisors’s AbbVie ABBV Stock Holding History

LM Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,170	Closed	-$455K	–	186
2025 Q1	$455K	Buy	+2,170	New	+$422K	0.08%	163
2024 Q1	–	Sell	-677	Closed	-$105K	–	218
2023 Q4	$105K	Buy	+677	New	+$98.7K	0.02%	251

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

LM Advisors's ABBV Position: Q2 2025 in Review

LM Advisors sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 2,170 shares — an estimated $455K sold.

LM Advisors first reported a position in ABBV in Q4 2023 and held it in 2 quarters. The position peaked at $455K in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

LM Advisors reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
LM Advisors sold 2,170 AbbVie shares in Q2 2025, an estimated $455K.
LM Advisors first reported a position in AbbVie in Q4 2023 and held it in 2 quarters.
LM Advisors's AbbVie position peaked at $455K in Q1 2025.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on LM Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.